Abbott Laboratories is an American worldwide healthcare company. With headquarters in Lake Bluff, Illinois, it has 94,000 employees and operates in more than 150 countries.
The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; it eventually grew to also sell research-based drugs, medical devices, diagnostics, and nutritional products. It split off the research-based pharmaceuticals into Abbvie in 2013. In 2015, revenues were $20.4 billion.
Abbott has a broad range of branded generic pharmaceuticals, medical devices, diagnostics, and nutrition products. The company’s in-vitro diagnostics business performs immunoassays and blood screening. Its medical tests and diagnostic instrument systems are used worldwide by hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, as well as assess other indicators of health. In 1985, the company developed the first HIV blood-screening test.
news29 July 2014 | By European Pharmaceutical Review
Clinical laboratories around the world are helping to improve patient care while navigating an evolving healthcare environment. To help laboratories with increasing demands, Abbott (NYSE: ABT) is developing diagnostic solutions for today and tomorrow, which it will showcase during the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical…
news14 July 2014 | By Abbott
Abbott announced that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company...
news11 July 2014 | By Abbott
A proposed strategic alliance with Fonterra to develop dairy farms is the latest in a series of investments Abbott has made in China...
news24 June 2014 | By Abbott
Abbott announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer...
news16 May 2014 | By Abbott
Abbott enhances its position in fast-growing Latin American market, more than doubling its branded generics pharmaceutical sales and presence in the region...
news12 May 2014 | By Abbott
Early study results suggest Abbott technology equivalent to current standard of care, but produces results much more quickly...
news15 April 2014 | By European Pharmaceutical Review
Abbott announced today that its new ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test – which can aid physicians in diagnosing and monitoring diabetes and identifying people at risk for the disease – has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). More than 25 million Americans are…
news10 April 2014 | By Abbott
Abbott announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™ Bioresorbable Vascular Scaffold...
news17 December 2013 | By Abbott
This highly advanced diagnostic tool measures the internal optics and surface of the eye more precisely than conventional methods...
news18 November 2013 | By Abbott
Abbott was recognized by The Deal as the best all-around dealmaker in healthcare...
news12 November 2013 | By European Pharmaceutical Review
With advances in medical treatments and an aging population, the demand for donated blood continues, as fewer people are becoming lifelong donors. 1In an effort to raise awareness about blood donation and encourage young adults to become repeat blood donors, Music Saves Lives® and Abbott are announcing a special opportunity…
news7 November 2013 | By Abbott
Similac is trying to meet that resource need with the launch of StrongMoms Español, a free program that provides Hispanic moms relevant, Spanish-language resources...
news30 October 2013 | By Abbott
The MitraClip device provides physicians with a breakthrough treatment option for patients suffering from MR...
news25 October 2013 | By Abbott
"With the MitraClip system, heart teams now have a catheter-based, less-invasive treatment option..."
news24 October 2013 | By Abbott
The annual survey is based on the views of working scientists...
